- Home
- YHNA vs MGX Comparison
YHNA vs MGX Comparison
Compare YHNA & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHNA
- MGX
- Stock Information
- Founded
- YHNA 2023
- MGX 2018
- Country
- YHNA Hong Kong
- MGX United States
- Employees
- YHNA N/A
- MGX N/A
- Industry
- YHNA
- MGX
- Sector
- YHNA
- MGX
- Exchange
- YHNA Nasdaq
- MGX NYSE
- Market Cap
- YHNA 79.9M
- MGX 70.4M
- IPO Year
- YHNA 2024
- MGX 2024
- Fundamental
- Price
- YHNA $10.04
- MGX $3.55
- Analyst Decision
- YHNA
- MGX Strong Buy
- Analyst Count
- YHNA 0
- MGX 7
- Target Price
- YHNA N/A
- MGX $16.67
- AVG Volume (30 Days)
- YHNA 10.8K
- MGX 4.5M
- Earning Date
- YHNA 01-01-0001
- MGX 02-12-2025
- Dividend Yield
- YHNA N/A
- MGX N/A
- EPS Growth
- YHNA N/A
- MGX N/A
- EPS
- YHNA N/A
- MGX N/A
- Revenue
- YHNA N/A
- MGX $55,080,000.00
- Revenue This Year
- YHNA N/A
- MGX $11.59
- Revenue Next Year
- YHNA N/A
- MGX N/A
- P/E Ratio
- YHNA N/A
- MGX N/A
- Revenue Growth
- YHNA N/A
- MGX 45.13
- 52 Week Low
- YHNA $9.99
- MGX $1.61
- 52 Week High
- YHNA $10.05
- MGX $12.74
- Technical
- Relative Strength Index (RSI)
- YHNA N/A
- MGX 64.37
- Support Level
- YHNA N/A
- MGX $2.91
- Resistance Level
- YHNA N/A
- MGX $3.63
- Average True Range (ATR)
- YHNA 0.00
- MGX 0.54
- MACD
- YHNA 0.00
- MGX 0.09
- Stochastic Oscillator
- YHNA 0.00
- MGX 55.66
About YHNA YHN Acquisition I Limited Ordinary Shares
YHN Acquisition I Ltd is a newly organized blank check company for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).